February 2020 PMID 32012227

Surfactant for pulmonary haemorrhage in neonates.

Abdul Aziz, Arne Ohlsson

Download social card

Mentions

4
Peak: 3 in Jan 2025
across 2 sources since Jan 2025

Extended reach

16,725
potential audience

Total likes

330

Video views

12,765

Mentions per month

Jan 2025 – Aug 2025

Where it's discussed

  • X / Twitter2 posts
  • YouTube2 videos

AI synopsis

What people are saying

The discussions revolve around the serious issue of pulmonary hemorrhages in neonates, with posts questioning why such bleeding occurs and how to treat it, exemplified by phrases like 'Why do neonates bleed from the lungs?' and 'how do you treat it??'. The tone is inquisitive and emphasizes the clinical problem, which indicates interest but limited depth of engagement or perceived high impact at this point.

AgreementNeither agree nor disagree

The discussions show some inquiry but do not explicitly affirm or oppose the research findings, indicating a neutral stance.

InterestModerate interest

The posts demonstrate curiosity about pulmonary hemorrhages and their treatment in neonates, reflecting moderate interest.

EngagementNeutral engagement

The posts pose questions about the causes and treatment of pulmonary hemorrhages, suggesting a basic level of engagement but not deep analysis.

ImpactNeutral impact

Given the brief, question-focused nature of the discussions, the perceived impact on clinical practice or theory seems minimal at this stage.

Abstract in brief

  • Pulmonary hemorrhage (PH) in neonates historically affected full-term infants with underlying health issues but now mainly occurs in preterm infants with severe respiratory distress syndrome (RDS), often associated with patent ductus arteriosus (PDA) and recent surfactant treatment.
  • The cause of PH is believed to be related to rapid lowering of intrapulmonary pressure, which promotes shunting across PDA and increases pulmonary blood flow; some studies suggest surfactant may help treat PH.
  • Research, including controlled trials, aims to evaluate the effectiveness of surfactant in reducing mortality and morbidity in neonates with PH by comparing surfactant treatment to placebo or no intervention, analyzing outcomes such as risk ratios and mean differences.

Top posts

Most liked on X and Bluesky
Tala Talks NICU
@Tala_Talks_NICU · X

Back into the swing of things- the horrible pulmonary hemorrhages: Why do NEONATES bleed from the LUNGS and how do you TREAT it?? https://t.co/3byvlZgCFn

Jan 21, 2025 · 4 likes · 1 share · 1,377 followers View post →
Daphna Yasova Barbeau, MD
@DoctorDaphnaMd · X

RT @Tala_Talks_NICU: Back into the swing of things- the horrible pulmonary hemorrhages: Why do NEONATES bleed from the LUNGS and how do you…

Jan 22, 2025 · 1 share · 2,579 followers View post →

All mentions

Daphna Yasova Barbeau, MD
@DoctorDaphnaMd · X

RT @Tala_Talks_NICU: Back into the swing of things- the horrible pulmonary hemorrhages: Why do NEONATES bleed from the LUNGS and how do you…

Jan 22, 2025 · 1 share · 2,579 followers View post →
Tala Talks NICU
@Tala_Talks_NICU · X

Back into the swing of things- the horrible pulmonary hemorrhages: Why do NEONATES bleed from the LUNGS and how do you TREAT it?? https://t.co/3byvlZgCFn

Jan 21, 2025 · 4 likes · 1 share · 1,377 followers View post →